Corvus Pharmaceuticals, Inc.
CRVS
$15.97
$0.161.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.69M | -12.32M | -10.16M | -8.00M | 15.19M |
| Total Depreciation and Amortization | 29.00K | 26.00K | 28.00K | 29.00K | 22.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.23M | 2.02M | 1.11M | -701.00K | -23.63M |
| Change in Net Operating Assets | 57.00K | 1.08M | -550.00K | 2.89M | 152.00K |
| Cash from Operations | -10.37M | -9.19M | -9.57M | -5.78M | -8.26M |
| Capital Expenditure | -91.00K | -25.00K | 0.00 | -113.00K | -36.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -144.76M | 10.91M | -2.62M | -20.19M | 4.28M |
| Cash from Investing | -144.85M | 10.88M | -2.62M | -20.30M | 4.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 190.75M | 20.00K | 360.00K | 35.77M | 279.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 190.75M | 20.00K | 360.00K | 35.77M | 279.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 35.53M | 1.71M | -11.82M | 9.69M | -3.74M |